SEMPER PARATUS ACQU -CW26 (TVGNW) Stock News

USA - NASDAQ:TVGNW -

0.0532 USD

0 (-7.16%)

Last: 9/17/2025, 11:49:22 AM

Technical Analysis

TVGNW Latest News, Press Relases and Analysis

All

Press Releases

7 days ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in Boston

7 days ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in Boston

8 days ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Estimates 5-Year Top-Line Revenue of ∼$6.5 Billion For Product Focused on Liver Cancer Prevention with High-Risk Chronic Hepatitis B Infection

8 days ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Estimates 5-Year Top-Line Revenue of ∼$6.5 Billion For Product Focused on Liver Cancer Prevention with High-Risk Chronic Hepatitis B Infection

9 days ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Values TVGN-489 at $9–$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell™ Allogeneic T Cell Platform

9 days ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Values TVGN-489 at $9–$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell™ Allogeneic T Cell Platform

13 days ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Shares Valuation of Key Assets and Potential Forecast For Pipeline Product Focused on EBV Associated Leukemia and Lymphomas

13 days ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Shares Valuation of Key Assets and Potential Forecast For Pipeline Product Focused on EBV Associated Leukemia and Lymphomas

14 days ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Underscores the Importance of Precision Immunotherapies, Including TVGN 489 for Vulnerable Individuals Infected with SARS-CoV-2

14 days ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Underscores the Importance of Precision Immunotherapies, Including TVGN 489 for Vulnerable Individuals Infected with SARS-CoV-2

21 days ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Bio Highlights Proprietary Assets and Upcoming Valuation Disclosure

21 days ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Bio Highlights Proprietary Assets and Upcoming Valuation Disclosure

22 days ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Expresses Gratitude to Yale for Recognition of Dr. Ryan Saadi and Company’s Mission of Health Equity

22 days ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Expresses Gratitude to Yale for Recognition of Dr. Ryan Saadi and Company’s Mission of Health Equity

23 days ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Sees Continued Growth in Institutional Ownership in Q2 2025; 72% of Holders Increased or Maintained Positions

23 days ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Sees Continued Growth in Institutional Ownership in Q2 2025; 72% of Holders Increased or Maintained Positions

26 days ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Recognized in BINJE’s BEST Health Care 2025 for Advancing Health Equity and Sustainable Biopharma

26 days ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Recognized in BINJE’s BEST Health Care 2025 for Advancing Health Equity and Sustainable Biopharma

a month ago - By: Tevogen Bio Inc - Mentions: TVGN

REPEAT -- Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts

a month ago - By: Tevogen Bio Inc - Mentions: TVGN

REPEAT -- Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts

a month ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Delivers Stronger Second Quarter and First Half 2025 Financial Results with Reduced Expenses and Growth Momentum

a month ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Delivers Stronger Second Quarter and First Half 2025 Financial Results with Reduced Expenses and Growth Momentum

a month ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen CEO Donates Personal Shares to Support Local Law Enforcement

a month ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen CEO Donates Personal Shares to Support Local Law Enforcement

a month ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen CEO Donates Personal Shares to Support Brain Injury Recovery

a month ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen CEO Donates Personal Shares to Support Brain Injury Recovery

a month ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen to Release Internal Asset Valuation; CEO Affirms Assets Are Fully Protected

a month ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen to Release Internal Asset Valuation; CEO Affirms Assets Are Fully Protected

a month ago - By: Tevogen Bio Inc - Mentions: TVGN

Repeat - Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology

a month ago - By: Tevogen Bio Inc - Mentions: TVGN MSFT

Repeat - Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology

a month ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Bio Reaffirms Investor Confidence with Estimated Asset Value Exceeding $10 Billion

a month ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Bio Reaffirms Investor Confidence with Estimated Asset Value Exceeding $10 Billion

a month ago - By: Tevogen Bio Inc - Mentions: TVGN

REPEAT -- Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 Billion

a month ago - By: Tevogen Bio Inc - Mentions: TVGN

REPEAT -- Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 Billion

a month ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Bio Oncology Reports Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to Follow

a month ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Bio Oncology Reports Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to Follow

a month ago - By: Tevogen Bio Inc - Mentions: TVGN

REPEAT - Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders

a month ago - By: Tevogen Bio Inc - Mentions: TVGN

REPEAT - Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders

a month ago - By: Tevogen Bio Inc - Mentions: TVGN

REPEAT - Tevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase Positions

a month ago - By: Tevogen Bio Inc - Mentions: TVGN

REPEAT - Tevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase Positions